- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Coronary vein.
Displaying page 1 of 2.
EudraCT Number: 2021-002343-30 | Sponsor Protocol Number: NEWTON-CABG | Start Date*: 2021-09-21 | |||||||||||
Sponsor Name:Unity Health Toronto, at its St. Michael’s site | |||||||||||||
Full Title: A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG) | |||||||||||||
Medical condition: Patency of graft after coronary bypass graft surgery in patients with hyprelipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023552-90 | Sponsor Protocol Number: BQ123CPBP2010 | Start Date*: 2011-05-05 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Abteilung für Herzchirurgie | ||||||||||||||||||||||||||||||||||||||
Full Title: Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting | ||||||||||||||||||||||||||||||||||||||
Medical condition: aorto-coronary bypass surgery in patients with coronary artery disease | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-004214-16 | Sponsor Protocol Number: FS014 | Start Date*: 2005-01-19 | |||||||||||
Sponsor Name:Committee of Management, Common Services Agency T/A Scottish National Blood Transfusion Service | |||||||||||||
Full Title: A randomised control clinical study to determine whether SNBTS Fibrin Sealant promotes wound healing in patients undergoing cardiac surgery. | |||||||||||||
Medical condition: In patients undergoing cardiac surgery the saphenous leg vein is used to replace veins used in coronary artery bypass grafts (CABG) surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005600-19 | Sponsor Protocol Number: APHP200072 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023839-42 | Sponsor Protocol Number: H8O-CY-O027 | Start Date*: 2011-04-29 | ||||||||||||||||
Sponsor Name:General University Hospital in Prague | ||||||||||||||||||
Full Title: EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs | ||||||||||||||||||
Medical condition: Patients with elective coronary artery bypass grafting with LV systolic dysfunction (EF LV ≤ 50%) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002142-50 | Sponsor Protocol Number: POPCABG03 | Start Date*: 2019-04-09 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. | ||
Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024485-21 | Sponsor Protocol Number: daisy | Start Date*: 2013-04-15 |
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||
Full Title: Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY | ||
Medical condition: Patients with a single ≥ 50% e <75% coronary stenosis (visually extimated) at angiography, in one ore more coronary vessels). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000013-36 | Sponsor Protocol Number: 49653/416 | Start Date*: 2005-08-17 |
Sponsor Name:Dr. Olivier F. Bertrand , Laval Hospital | ||
Full Title: A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression after Coronary Bypass Surgery in Diabetic Patients | ||
Medical condition: Atherosclerosis progression in vein grafts in diabetic patients after coronary bypass surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000238-16 | Sponsor Protocol Number: APD791-202 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane... | |||||||||||||
Medical condition: Microvascular Obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005960-95 | Sponsor Protocol Number: 2006UK-001 | Start Date*: 2006-04-26 |
Sponsor Name:Enturia, Inc. | ||
Full Title: Prospective, randomised clinical trial to compare the efficacy of 0.5% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol with 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alco... | ||
Medical condition: This product is a skin disinfectant and therefore is not specific for a medicinal condition. It will be used where patients require skin disinfection prior to surgery and for care of the surgical ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001069-28 | Sponsor Protocol Number: D5881C00004 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH) | |||||||||||||
Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004220-23 | Sponsor Protocol Number: VIDEAT | Start Date*: 2008-09-04 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECT OF SUPPLEMENTATION WITH CHOLECALCIFEROL ON GLUCOSE AND LIPID METABOLISM, BLOOD PRESSURE, BONE MASS, QUALITY OF LIFE, CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH ISCHAEMIC HEART D... | |||||||||||||
Medical condition: ISCHAEMIC ARTERY DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005410-19 | Sponsor Protocol Number: HH-AT-001 | Start Date*: 2013-03-11 | |||||||||||
Sponsor Name:Jessaziekenhuis Hasselt | |||||||||||||
Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants. | |||||||||||||
Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004877-38 | Sponsor Protocol Number: PREVENT-MINS | Start Date*: 2021-06-18 | |||||||||||
Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum | |||||||||||||
Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial | |||||||||||||
Medical condition: Myocardial Injury after Noncardiac Surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004082-25 | Sponsor Protocol Number: D5130C00137 | Start Date*: 2015-03-27 | |||||||||||
Sponsor Name:Hellenic Cardiovascular Research Society | |||||||||||||
Full Title: A multicenter, prospective, randomized, open label, blinded endpoint, active-comparator trial to assess the MIcrovascular integrity and left ventricular function Recovery after clopidogrel or Ticag... | |||||||||||||
Medical condition: Patients with Myocardial Infarction with ST-segment elevation (STEMI) undergoing thrombolysis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003125-39 | Sponsor Protocol Number: TRI-08892 | Start Date*: 2020-10-12 |
Sponsor Name:Thrombosis Research Institute | ||
Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap... | ||
Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-000934-77 | Sponsor Protocol Number: 4.0 | Start Date*: 2018-05-11 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery | ||
Medical condition: Patients referred for CABG to the Department of Cardiac Surgery with planned isolated left mammary artery and vein/radial artery grafts preparation will be asked to participate in this trial. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001559-15 | Sponsor Protocol Number: CTO#2095 | Start Date*: 2022-11-11 | |||||||||||
Sponsor Name:Ottawa Hospital Research Institute | |||||||||||||
Full Title: StAtins for Venous Event Reduction in Patients with Venous Thromboembolism | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001975-30 | Sponsor Protocol Number: BAY59-7939/17938 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ... | |||||||||||||
Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001319-26 | Sponsor Protocol Number: FJD-COVID-ESTATINAS | Start Date*: 2020-05-14 |
Sponsor Name:Instituto de Investigación Sanitaria Fundación Jiménez Díaz | ||
Full Title: Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. | ||
Medical condition: COVID respiratory infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
